International Women’s Day 2021: Q&A with Kate Bache, co-founder & managing director of Health and Her

No items found.
​
March 8, 2021

This year, the International Women’s Day theme is ‘choose to challenge’ with a focus on challenging change to create a gender equal world.

The day marks a call to action for accelerating women’s equality, celebrating women’s achievements and raising awareness against bias. Throughout the year, we have observed EIP clients who are committed to improving gender equality and today we are celebrating them.

About Health & Her®

Health & Her® is an award-winning health hub that aims to cut through the confusion when it comes to female health. Health & Her provides advice and support from the UK’s leading menopause experts via their expert articles and Menopause Clinic. They offer a range of the best products from around the world to support perimenopause and menopause symptoms and a free ‘personal trainer’ app designed to coach women through menopause.

Health & Her are on a mission to improve lives of millions of women around the world living with life-affecting symptoms of menopause.

Meet Kate Bache

Originally a qualified chemist (MChem), Kate quickly moved into commercial roles and has more than 13 years’ experience in blue chip pharmaceutical and FMCG companies.

Kate has held senior marketing and innovation positions in international functions across Europe and Australasia for Reckitt Benckiser, Kellogg’s and PepsiCo. A specialist in international innovation, commercialisation and marketing leadership, Kate initially started her entrepreneurial endeavours by founding and successfully exiting successful femcare brand, KIND Organic.

It was during this time, Kate discovered the complete lack of support for women experiencing severe symptoms of female health and in particular the poor availability of products and solutions for women experiencing menopause.

Hi Kate. Could you tell us more about what made you want to start Health and Her?

My initial research unearthed some shocking statistics related to this stage of women’s lives with the highest rates of divorce, suicide and job leavers associated with women aged 45-55. Further studies conducted by Health & Her showed the far-reaching impact of these issues with the UK economy losing 14 million days a year[1] to women managing symptoms associated with menopause. This equates to £1.8bn GDP lost annually.

There was a clear gap in the market for a resource where women could understand their choices, discover information and find solutions and so Health & Her was born.

Where do you see the femtech industry being in five years’ time?

Femtech is an incredibly exciting industry at the moment with very high levels of innovation that are directly impacting on women’s lives. For me, the most exciting direction of travel is towards highly personalised solutions based on an individual’s hormones. I believe that in 5 years’ time, we could see ideas which would significantly improve women’s female health symptoms through passive diagnostic and delivery technology.

How has the growing discussion about women's health affected your business?

Menopause in particular has become a hot topic in recent years and this has certainly allowed us to talk more directly to women about their options. There’s still a long way to go vs. other women’s health issues such as periods and fertility but as these younger generations start to move toward perimenopause, we hope that their openness to these subjects will translate into menopause and the topic gets the airtime it needs to improve the lives of millions of women.

How can everyone get involved in supporting smarter women’s health?

This International Women's day we want to #ChooseToChallenge the taboos around Menopause and open the conversation for us all to talk about the symptoms of perimenopause and menopause and how they impact the millions of women in the UK.

Women’s health doesn’t just affect women. Fathers, brothers, husbands, sons and society as a whole are affected by the challenges of female health. We have an incredibly long way to go to solve the issues that millions of women face every day and I believe that we need everyone to realise this to make significant and lasting change for the better.

[1] Censuswide survey, 1003 menopausal women, UK, 2019

At EIP, we are committed to diversity and inclusion. We believe in equal opportunity in all areas and we are proud that diversity is a core part of our culture.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​